The immunohistochemical findings–scarce S100 and focal CD34—strongly suggest a loss of the typical neurofibroma architecture (specifically, loss of the CD34-positive fibroblastic network), likely fulfilling a third criterion [8]. The gene discussed is CD34; the disease is neurofibroma.